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Within the past years, an important role for nitric oxide
(NO) in skin repair has been well de¢ned. As NO is
synthesized from L-arginine by NO synthases (NOS),
the availability of L-arginine might be one rate-limiting
factor of NO production at the wound site. Upon in-
jury, arginase-1 and -2 mRNA, protein, and activity
were strongly induced reaching a maximum between
day 3 and day 7 postwounding. Immunohistochemistry
colocalized both arginases and the inducible NOS
(iNOS) at epithelial sites at the margins of the wound.
Notably, diabetes-impaired skin repair in leptin-de¢-
cient mice (diabetes/diabetes, db/db; and obese/obese,
ob/ob) was characterized by an abnormally elevated ar-
ginase activity in wound tissue in the absence of an ex-
pression of iNOS. Expression analyses demonstrated
that arginase-1 contributed to increased arginase activ-
ities in impaired repair. Interestingly, an improved
healing of chronic wound situations in leptin-supple-
mented ob/ob mice was strongly associated with an ad-
justment of the dysregulated expression of L-arginine-
converting enzymes: an attenuated iNOS expression
was upregulated early in repair and an augmented argi-
nase-1 expression and activity was downregulated in
the presence of markedly elevated numbers of macro-
phages during late repair. These data suggest a coordi-
nated consumption of L-arginine by the NOS and
arginase enzymatic pathways at the wound site as a
prerequisite for a balanced NO (via iNOS) and polya-
mine (via arginases) synthesis that drives a normal skin
repair. Key words: L-arginine/keratinocyte/wound healing/
leptin/inducible nitric oxide synthase. J Invest Dermatol
121:1544 ^1551, 2003
T
o overcome tissue damage, the process of cutaneous
wound repair represents a highly ordered process that
is characterized by temporally and spatially overlap-
ping phases of tissue movements comprising hemor-
rhage, in£ammation, reepithelialization, granulation
tissue formation, and the late remodeling phase of repair. As a
result, the integrity of the body’s protective layer is maintained,
although repair fails to perfectly replace the original skin tissue.
Loss of a functional healing process might lead to severe dis-
abilities. Accordingly, chronic, nonhealing wound conditions
represent a situation of major clinical importance. A series of pa-
thologic changes accompanied with several diseases ¢nally leads
to severely disturbed wound healing conditions. Among those,
the most prominent chronic wound situations are known as
decubitus or pressure ulcers, venous ulcers, and diabetic ulcers
(Falanga, 1993).
The factors mediating the intercellular communication during
wound repair are known in part, but their number is still increas-
ing. Proin£ammatory cytokines and various peptide growth fac-
tors are known to be key players in this process (Martin, 1997;
Singer and Clark, 1999). Nevertheless, these protein-type factors
are not unique in regulating cellular behavior in skin biology,
and nitric oxide (NO), a small di¡usible radical gas, has been de-
monstrated an important role in wound repair (Frank et al, 2002).
Especially, the inducible NO synthase (iNOS) isoenzyme is
strongly upregulated upon skin injury (Frank et al, 1998). Inhibi-
tion of iNOS enzymatic activity during repair in wild-type mice
using N6-(iminoethyl)-L-lysine resulted in a similar delay in
complete wound closure (Stallmeyer et al, 1999) compared to in-
jured iNOS knockout mice (Yamasaki et al, 1998). Inhibition of
iNOS enzymatic activity during skin repair was paralleled by a
severely impaired reepithelialization process, because the epithe-
lial sites at the margins of the wound were characterized by an
atrophied morphology and strongly reduced numbers of prolifer-
ating keratinocytes (Stallmeyer et al, 1999).
These observations provide a strong explanation for the well-
known fact that L-arginine is implicated in wound healing, be-
cause the amino acid L-arginine represents the only substrate for
NOS enzymatic activity. An early study from nearly 25 years ago
demonstrated the in£uence of L-arginine supplementation to im-
prove wound healing in a rat model of incisional repair (Seifter
et al, 1978). Consistently, the bene¢cial e¡ect of L-arginine
observed in animal models turned out to be true also in humans.
Clinical studies demonstrated an enhanced wound healing in
L-arginine-supplemented patients, which was characterized by a
markedly increased wound collagen deposition (Barbul et al,
1990; Kirk et al, 1993).
Nevertheless, iNOS activities most likely face an antagonistic
player that might strongly compete for the L-arginine substratum
at the wound site. It is tempting to speculate that arginases, which
turn over L-arginine into ornithine and urea, might in£uence
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wound NO production by limiting iNOS substrate. In line, L-ar-
ginine levels in wound £uids remain low during healing, because
the amino acid is subject to the catalytic activity of arginase in
late repair, releasing measurable amounts of ornithine into the
wound £uid (Albina et al, 1990). It is important to recognize that
two distinct arginase isoenzymes exist in mammals that are en-
coded by separate genes. Although enzymatic properties were
nearly similar, both enzymes di¡er in subcellular localization, tis-
sue expression, and expressional regulation (Grody et al, 1987;
Jenkinson et al, 1996). As part of the urea cycle, arginase-1 is pre-
dominantly expressed in liver, whereas the mitochondrial argi-
nase-2 isoenzyme seems to be more ubiquitously expressed.
Nevertheless, although much work has been focused on the
NOS axis of L-arginine turnover in the context of wound heal-
ing, only limited data are available for the arginases. To this end,
we determined arginase expression and activity in animal models
of normal and impaired repair. Our data suggest that expression
and activity of both arginase isoenzymes were induced upon skin
injury, but, interestingly, only a dysregulated arginase-1 activity
was associated with impaired wound healing conditions.
MATERIALS AND METHODS
Animals Female BALB/c or C57BLKS mice were obtained from
Charles River (Sulzfeld, Germany). Female C57BL/6 J-ob/ob and
C57BLKS/J-mþ /þ Leprdb (db/db) mice were obtained from The Jackson
Laboratories (Bar Harbor, ME). The homozygous animals develop
characteristics similar to those of human adult onset diabetes (Coleman,
1982). Mice were maintained under a 12-h light/12-h dark cycle at 221C
until they were 8 wk of age. At this time they were caged individually,
monitored for body weight and wounded as described below.
Treatment of mice Murine recombinant leptin (Calbiochem, Bad
Soden, Germany) was injected intraperitoneally once a day at 8 a.m.
(2 mg/g body weight) in 0.5 mL of phosphate-bu¡ered saline (PBS) per
injection for 13 d.
Wounding of mice Wounding of mice was performed as described
previously (Frank et al, 1999; Stallmeyer et al, 1999). Brie£y, mice were
anesthetized with a single intraperitoneal injection of ketamine (80 mg/kg
body weight)/xylazine (10 mg/kg body weight). The hair on the back of
each mouse was cut, and the back was subsequently wiped with 70%
ethanol. Six full-thickness wounds (5 mm in diameter, 3^4 mm apart)
were made on the back of each mouse by excising the skin and the
underlying panniculus carnosus. The wounds were allowed to form a
scab. Skin biopsy specimens were obtained from the animals 1, 3, 5, 7, 10,
and 13 d after injury. At each time point, an area that included the scab and
the complete epithelial margin was excised from each individual wound.
As a control, a similar amount of skin was taken from the backs of
nonwounded mice. For each experimental time point, tissue from four
wounds each from four animals (n¼16 wounds, RNA analysis) and from
two wounds each from four animals (n¼ 8 wounds, protein analysis) were
combined and used for RNA and protein preparation. Nonwounded back
skin from four animals served as a control. All animal experiments were
carried out according to the guidelines and with the permission from the
local government of Hessen (Germany).
RNA isolation and RNase protection analysis RNA isolation and
RNase protection assays were carried out as described previously
(Chomczynski and Sacchi, 1987; Frank et al, 1999). Brie£y, 20 mg of total
RNA from wounded or nonwounded skin was used for RNase
protection assay. DNA probes were cloned into the transcription vector
pBluescript II KS(þ ) (Stratagene, Heidelberg, Germany) and linearized.
An antisense transcript was synthesized in vitro using T3 or T7 RNA
polymerase and [a-32P]UTP (800 Ci/mmol). RNA samples were hybri-
dized at 421C overnight with 100,000 cpm of the labeled antisense
transcript. Hybrids were digested with RNases A and T1 for 1 h at 301C.
Under these conditions, every single mismatch is recognized by the
RNases. Protected fragments were separated on 5% acrylamide/8 M urea
gels and analyzed using a PhosphoImager (Fuji, Straubenhardt, Germany).
RNases A and T1were from Roche Biochemicals (Mannheim, Germany).
The murine cDNA probes were cloned using RT-PCR. The probes
corresponded to nucleotides 362^660 (for arginase-1, Accession No.
U51805), nucleotides 360^619 (for arginase-2, Accession No. U90886),
nucleotides 3285^3574 (for iNOS, Accession No. NM010927), nucleotides
425^446 (exon 1) and 150^170 (exon 2) (for lysozyme M, Accession Nos.
M21047, M21048), or nucleotides 163^317 (for GAPDH, Accession No.
NM002046) of the published sequences.
Preparation of protein lysates and Western blot analysis Skin and
cell culture samples were homogenized in lysis bu¡er (1% Triton X-100,
20 mM Tris/HCl, pH 8.0, 137 mM NaCl, 10% glycerol, 5 mM
ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl £uoride,
1% aprotinin, 15 mg/mL leupeptin). The extracts were cleared by
centrifugation (Kmpfer et al, 1999; Stallmeyer et al, 1999). Fifty micro-
grams of total protein from skin or cellular lysates was separated using
SDS-gel electrophoresis. After transfer to a polyvinylidene di£uoride
membrane, arginase-1 and -2 protein was detected using polyclonal anti-
bodies against rat arginase-1 and -2. The arginase antibodies had been
generated in rabbits using speci¢c peptide sequences (arginase-1, H2N-
CEGNHKPETDYLKPPK-COOH; arginase-2, H2N-CHLPTPSSPHE
SEKEE-COOH). The rabbit polyclonal antibody against murine iNOS
was purchased from Alexis Corporation (Grˇnberg, Germany). A
secondary antibody coupled to horseradish peroxidase and the ECL
detection system were used to visualize the Arg-1 and -2 proteins,
respectively. Phenylmethylsulfonyl £uoride, aprotinin, and leupeptin were
from Sigma (Deisenhofen, Germany) or Roche Biochemicals. The ECL
detection system was obtained from Amersham (Freiburg, Germany).
Immunohistochemistry Mice were wounded as described above.
Animals were euthanized at day 5 after injury. Complete wounds were
isolated from the back, bisected, and frozen in tissue freezing medium.
Six-micrometer frozen sections were ¢xed with acetone and treated for 10
min at room temperature with 1% H2O2 in PBS to inactivate endogenous
peroxidases. They were subsequently incubated overnight at 41C with
rabbit polyclonal antisera against rat arginase-1, arginase-2, murine iNOS,
or murine macrophage (mf)-speci¢c F4/80 antigen (1:50 diluted in PBS,
0.1% bovine serum albumin), respectively (Stallmeyer et al, 1999). The
antiserum against murine mf-speci¢c F4/80 antigen was from SeroTec
(Hamburg, Germany).
Arginase activity assay Arginase activity was determined as described
(Corraliza et al, 1994). Brie£y, isolated wound tissue was homogenized in 25
mM Tris-HCl, pH 7.5/5 mM MnCl2 in the presence of protease inhibitors
(10 mg/mL pepstatin A, 10 mg/mL leupeptin, 100 mg/mL phenylmethyl-
sulfonyl £uoride). Homogenates were cleared by centrifugation (20 min,
5000 g). Equal amounts of total wound protein were subsequently
activated for arginase activity at 551C for 10 min. L-Arginine was added,
and activated homogenates were incubated at 371C for 1 h. The arginase
reaction was terminated by addition of an eightfold excess (vol/vol) of
H2SO4, H3PO4, and H2O (1:3:7). 1-Phenyl-1,2-propanedione-2-oxime
was added for 30 min at 1001C. The amount of total urea formed was
subsequently determined spectrophotometrically at 540 nm. Results were
expressed as mg of urea per mg of protein per h.
Cell culture Quiescent murine PAM 212 epidermal keratinocytes were
stimulated with a combination of cytokines (2 nM interleukin-1b, 2 nM
tumor necrosis factor-a, 100 U per mL interferon-g) or 1 mM N6,20 -O-
dibutyryladenosine 30,50 -cyclic monophosphate (Bt2-cAMP). Bt2-cAMP
was purchased from Sigma, and cytokines were from Roche Bio-
chemicals (Mannheim, Germany).
Statistical analysis Data are shown as means7SD. Data analysis was
carried out using the unpaired Student’s t test with raw data. Statistical
comparison between more than two groups was carried out by ANOVA
(Dunnett’s method).
RESULTS
Skin injury induced a marked induction of arginase
expression and activity It is now well established that skin
injury is accompanied by the induction of iNOS during the
in£ammatory phase of repair (Frank et al, 1998, 2002). Moreover,
inhibitor studies using the partially selective iNOS inhibitor N6-
(iminoethyl)-L-lysine suggested the iNOS as the major source of
NO synthesis at the wound site (Frank et al, 1999). Because
L-arginine, additionally, represents the only substrate also for
arginase isoenzymes, we now investigated the expressional
regulation of arginase-1- and arginase-2 upon skin injury. Not
unexpected, both arginase isoenzymes were strongly induced at
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the mRNA (Fig 1a,b, top panels) and the protein (Fig 1a,b, bottom
panels) level after skin wounding. It is noteworthy that injury-
mediated induction of the arginases was characterized by a
temporal delay, as both proteins were only hardly detectable
24 h after wounding (1d wound). Because we had generated poly-
clonal antibodies against both arginase proteins using peptide
sequences from rat arginase-1 and -2, respectively (see Materials
and Methods), we tested the speci¢city of the obtained antisera
to unequivocally con¢rm our immunoblot data from wound
tissue. As arginase-1 is strongly and predominantly expressed in
liver tissue (Wu and Morris, 1998), we used total protein isolated
from murine liver as a positive control for the anti-arginase-1
antiserum (Fig 1c). Additionally, as arginase-2 has been reported
to be under positive regulatory control of the cAMP second
messenger pathway in the murine mf-like cell line RAW264.7
(Gotoh et al, 1996; Morris et al, 1998), we used cell lysates from
Bt2-cAMP-stimulated RAW264.7 cells to prove speci¢city of
the arginase-2 antiserum (Fig 1d). Speci¢city of both antibodies
was further veri¢ed, because, notably, anti-arginase-1 did not
detect the cAMP-inducible arginase-2 isoform in RAW264.7
lysates (Fig 1c), and anti-arginase-2 did not bind to the liver-
expressed arginase-1. Obviously, both antisera speci¢cally
recognized their respective arginase isoforms.
As a next step, we assessed the overall arginase activity in
nonwounded skin and wound tissue. To this end, equal amounts
of isolated skin or wound protein were incubated with L-
arginine, and the amount of generated urea was determined. As
shown in Fig 2, the observed induction of both arginase
isoenzymes was consistently followed by a marked increase of
total arginase activity in wound tissue, which remained even
slightly elevated at day 13 after injury. Nevertheless, it is
important to note that the overall activity shown in Fig 2
re£ects the enzymatic activities of both arginase isoenzymes at
the wound site. Interestingly, the delayed induction of arginase-
1 and -2 expression early after wounding (Fig 1a,b, bottom panels,
1d wound) was clearly re£ected by a slight decrease in arginase
activity in 1-d wound tissue (Fig 2).
L-Arginine-converting enzymes were colocalized at epithelial
sites in the wound tissue Next, we determined the
localization of both arginases in wound tissue. We investigated
tissue sections from 5-d wounds, because this time point of
healing was characterized by maximal expression both of
arginase isoenzymes (Fig 1a,b) and of the presence of iNOS
(Frank et al, 1998) (see also Fig 4e). As shown in Fig 3, both
arginase-1 and arginase-2 were expressed in wound margin kera-
tinocytes. Whereas the main body of proliferating keratinocytes
that usually builds up the hyperproliferative epithelium revealed
only small or even no arginase immunoreactivity, marked
immunopositive signals for arginase-1 and arginase-2 protein
could be detected in epidermal keratinocytes directly adjacent to
the massive hyperproliferative epithelia. Moreover, it is note-
Figure1. Expression of arginases upon skin
wounding. Regulation of arginase-1 (a) and
arginase-2 (b) mRNA (top panels) and protein
(bottom panels) expression in BALB/c mice as as-
sessed using the RNase protection assay or im-
munoblot. The time after injury is indicated at
the top of each lane. Ctrl skin, back skin biopsies
of nonwounded mice. Ctrl skin #2, non-
wounded skin of an additional experimental
series. 1000 cpm of the hybridization probe was
added to the lane labeled probe. A quanti¢cation
of arginase-1 and arginase-2 mRNA (x-fold in-
duction compared to control skin) is shown in
the middle panels. po0.05 (ANOVA, Dunnett’s
method) compared to control skin. Bars,
mean7SD obtained from wounds (n¼ 48) iso-
lated from animals (n¼12) from three indepen-
dent animal experiments. x-fold induction,
directly to control skin, because we always ex-
perienced an induction of GAPDH mRNA ex-
pression after wounding. Total protein (50 mg)
from murine liver- (c) or Bt2-cAMP- (1 mM)-
stimulated RAW 264.7 mf (d) was used to con-
trol the speci¢city of the anti-arginase antisera
as indicated.
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worthy that, especially, keratinocytes that were in direct contact
with the developing granulation tissue, showed a marked
immunoreactivity against arginase-1 and arginase-2 (Fig 3a,b,
insets). Interestingly, it must be recognized that iNOS was nearly
coexpressed at the same cellular sources in wound tissue (Fig 3c).
Because expression of both arginase isoenzymes during repair
(Fig 1a,b) resembled the in¢ltration kinetics of mf into the
wounded site, we assessed the presence of mf in 5-d wound
tissue using the mf-speci¢c F4/80 antigen (Fig 3d). Notably,
in¢ltrating immune cells, which were predominantly
represented by activated mf at day 5 postwounding (Fig 3d),
were not the major cellular source of arginase as well as iNOS
expression, because iNOS-, arginase-1-, and arginase-2-immuno-
positive signals were only sparsely located within the granulation
tissue. Evidently, cultured murine PAM 212 keratinocytes were
also capable of expressing both arginases and iNOS in vitro, thus
suggesting the overall capacity of keratinocytes of expressing
these enzymes in general (Fig 3e). Please note that Th1 cytokines
moderately reduced arginase-1 expression in the cells.
Arginase-1 and -2 expression and activity were strongly
dysregulated in chronic wound healing conditions As a
next step, we investigated the regulation of arginase expression
and activity in a mouse model of diabetes-impaired wound
healing. Diabetes/diabetes (db/db) mice are leptin-resistant (Chen
et al, 1996; Lee et al, 1996) and, thus, su¡er from severe metabolic
disorders. Moreover, these animals are characterized by severe
wound healing disorders (Wetzler et al, 2000). Not unexpected,
arginase-1 as well as arginase-2 were induced upon injury in db/
db mice (Fig 4a,c, bottom panels) and the expression kinetics were
similar to healthy control mice (Fig 1), especially with respect to
the observed delayed induction of both enzymes. Nevertheless,
analysis of mRNA expression in db/db mice revealed that both
arginases were not signi¢cantly di¡erent in nonwounded skin
but became dysregulated at late time points of repair (Fig 4a,c,
top panels). In contrast to healthy animals (wt), diabetes-impaired
repair (db) was characterized by a strong overexpression of both
arginase isoforms at the mRNA level. It is important to note
that the indicated experimental time points re£ect the phase
when an initiated healing in these mice transfers into chronic,
nonhealing wound conditions (Wetzler et al, 2000). Consistent
with the mRNA data, we found markedly elevated levels of
arginase-1 protein in chronic wounds (days 10 and 13) compared
to wounds isolated from control animals (Fig 4a,b). Nevertheless,
and as a surprise, arginase-2 protein expression appeared to be
counterregulated with respect to its own mRNA and, addi-
tionally, when compared to arginase-1. Although arginase-2-
speci¢c mRNA was strongly overexpressed in chronic wounds
(Fig 4c, top panel), we could only barely detect arginase-2
protein in chronic wounds (Fig 4c, bottom panel; Fig 4d). Note
that arginase-2 protein expression was still present at the end of
acute repair in normal healing (Figs 1b, 4d, top panel), a time point
of repair that was characterized by the absence of arginase-2
protein in db/db mice (Fig 4c,d). Additionally and to comple-
ment our data on the arginases, we had to recognize that the
iNOS, which competes with the arginases for the substrate at
the wound site, was not induced in db/db animals (Fig 4e).
Arginase activity was strongly induced in db/db mice after
injury (Fig 5) As described for healthy animals, we again
observed a reduction of arginase activity in early wounds (day
1), which was subsequently followed by a tremendous increase
within the next days. Nevertheless, the restricted expression of
only arginase-1 protein in the presence of markedly elevated
Figure 2. Arginase activity at the wound site. Arginase activity assay
in tissue homogenates from nonwounded and wounded back skin isolated
from BALB/c mice. The time after injury is indicated. Arginase activity is
given as mg of urea per mg of protein per h. po0.05 (ANOVA, Dunnett’s
method) compared to back skin of healthy mice. Bars, mean7SD obtained
from wounds (n¼ 8) isolated from animals (n¼ 4) from independent ani-
mal experiments.
Figure 3. Colocalization of arginase-1, arginase-2, and iNOS pro-
tein in regenerating skin. Frozen serial sections from mouse wounds
(day 5 postwounding) were incubated with polyclonal antisera directed
against arginase-1 (a), arginase-2 (b), iNOS (c), and mf-speci¢c F4/80 anti-
gen (d), respectively. All sections were stained with the avidin^biotin^per-
oxidase complex system using 3,3-diaminobenzidine tetrahydrochloride as
a chromogenic substrate. Nuclei were counterstained with hematoxylin.
Immunopositive signals within the sections are indicated with arrows.
Wound margin and inner wound area are indicated. g, granulation tissue;
he, hyperproliferative epithelium; iwa, inner wound area; Mf, macro-
phages; wma, wound margin. (e) Murine keratinocytes express arginase-1,
arginase-2, and iNOS in vitro. Quiescent murine PAM 212 keratinocytes
were stimulated with cytokines (cytmix, 2 nM interleukin-1b, 2 nM tumor
necrosis factor-a, 100 m/mL interferon-g) or Bt2-cAMP (1 mM) for 24 h.
RNase protection assay to detect arginase-1-, arginase-2-, or iNOS-speci-
¢c mRNAwas performed as indicated. Ctrl, nonstimulated cells. One re-
presentative experiment is shown.
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arginase activity in late chronic wounds strongly argues for
arginase-1 as the functionally predominant isoform that
contributed to an impaired repair. Moreover, it was interesting
to recognize that the overall induction of arginase activity was
even greater in diabetic mice (about sixfold, Fig 5) compared to
control animals (about twofold, Fig 2).
Reversal of chronic wound conditions in diabetic mice read-
justs the dysregulated arginase expression and activity Leptin-
de¢cient obese/obese (ob/ob) mice resemble a disturbed metabolic
phenotype similar to db/db mice. In contrast to db/db mice, which
do not express a functional leptin receptor (Chen et al, 1996;
Lee et al, 1996), ob/ob mice are characterized by a de¢ciency of
functional ligand (Zhang et al, 1994). Consistently, ob/ob mice
also su¡er from severe wound healing disorders. Nevertheless,
ob/ob mice represent an ideal model system to analyze, at least
partially, tissue movements that were associated to the transition
of a chronic toward regenerative healing conditions. Systemic
supplementation of leptin-de¢cient ob/ob mice with recombinant
leptin dramatically improves the metabolic disorders (Halaas et al,
1995) and subsequently strongly improves wound healing in the
animals (Frank et al, 2000b; Ring et al, 2000). Thus, ¢nally, we
investigated the regulation of arginases under conditions of
improved repair in ob/ob animals. Mice were treated with either
PBS or recombinant leptin over a time period of 13 d after
injury. As shown in Fig 6a, we could prove the systemic
availability and activity of the injected recombinant leptin,
because blood glucose levels rapidly readjusted to physiologic
levels after injection and because leptin-treated animals lost
nearly 30% of their body weight within 13 d of leptin
treatment. Moreover, healing wounds lose their scab coverage
after complete reepithelialization and completion of the acute
phase of repair. Histologic analysis demonstrated that lep-
tin-improved repair was characterized by reepithelialized
wounds about day 7 postwounding in ob/ob mice. By contrast,
wounds of PBS-treated ob/ob control mice were reepithelialized
around day 11 after injury (data not shown). Nevertheless and in
contrast to leptin-improved repair, the observed neoepithelia in
PBS-treated mice remained covered by a scab (Fig 6a). Thus, we
observed an accelerated wound healing in leptin-treated animals
(Fig 6a, bottom right panel) that was consistent with recently
published data (Frank et al, 2000b; Ring et al, 2000). As a
next step, we determined arginase-1 and -2 mRNA expression
in late wounds of PBS- and leptin-injected ob/ob mice. In
line with the data obtained in db/db animals, both arginase
isoforms were strongly overexpressed at the mRNA level in
chronic wounds (day 13). Evidently, leptin-improved repair
(Fig 6a, right panel) mediated a strong reduction of overshoot-
ing arginase mRNA expression (Fig 6b). Arginase-1 pro-
tein expression, as was also the case in chronic wounds of db/db
mice, paralleled its mRNA expression and declined (Fig 6c, left
panel). Nevertheless, arginase-2 protein, again, was counter-
regulated with respect to its mRNA. Leptin-improved healing
was characterized by decreasing arginase-2 mRNA (Fig 6b) and
increased protein levels (Fig 6c, right panel). Nevertheless, overall
arginase activity markedly declined after leptin treatment in
healing wounds, again suggesting arginase-1 as the functionally
predominant arginase isoform (Fig 6d). Finally, we showed that
leptin-improved repair, additionally, was characterized by a
Figure 4. Dysregulation of arginase expression during impaired
repair. Regulation of arginase-1 (a,b), arginase-2 (c,d), and iNOS (e) expres-
sion in diabetic db/db mice as assessed using the RNase protection assay and
immunoblot. The time after injury is indicated at the top of each lane. Ctrl
skin, back skin biopsies of nonwounded mice. For (a,c,e), every experimental
data point refers to 16 wounds (n¼16) isolated from four mice for RNA or
8 wounds (n¼ 8) from four mice for protein analysis, respectively. One re-
presentative experiment is shown. GAPDH mRNA expression is shown as
a loading control. A Ponceau S staining of the immunoblot is shown as a
loading control for (a,c). For (b,d), every data point refers to a total of 4
wounds isolated from a healthy (C57BLKS) or diabetic (db/db) individuals
(#1^#3). A quanti¢cation of arginase-1 and arginase-2 protein is shown
in (b,d, bottom panels). po0.01 (Student’s t test) as indicated by the bracket.
Figure 5. Increased arginase activity in chronic wounds. Arginase
activity assay in tissue homogenates from nonwounded and wounded back
skin isolated from diabetic db/db mice. The time after injury is indicated.
Arginase activity is given as mg of urea per mg of protein per h. po0.05
(ANOVA, Dunnett’s method) compared to back skin of healthy mice. Bars,
mean7SD obtained from wounds (n¼ 8) isolated from animals (n¼ 4)
from independent animal experiments.
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reinduction of a downregulated iNOS expression at the early
phase of repair (Fig 6e,f ). Nevertheless, although immuno-
histochemical analysis has localized both arginases in wound
keratinocytes during normal repair (Fig 3), it was tempting to
argue that the persistence of in£ammatory in¢ltrate might
explain the alterations in time course and magnitude of arginase
expression in slowly healing wounds of diabetic mice.To this end,
we analyzed 13-d wounds of leptin- and PBS-treated ob/ob mice
for the presence of mf. To do so, we ¢rst assessed mRNA
expression of lysozyme M, a gene that is constitutively expressed
in and speci¢c for mature mf (Cross et al, 1988; Wetzler et al,
2000). Surprisingly, we could not observe any signi¢cant
alteration in numbers in wounds (as assessed by lysozyme M
mRNA expression) from leptin- and PBS-treated ob/ob mice (Fig
6g), although, remarkably, wounds from leptin-injected, but not
from PBS-injected, animals were completely closed at this time
of repair (Fig 6a, right panel) (Frank et al, 2000b). To further
strengthen this observation, we speci¢cally immunolocalized mf
at the wound site. In line, sections of 13-d wounds isolated from
leptin-treated as well as PBS-treated ob/ob mice were characterized
by huge numbers of mf (Fig 6h). Thus, this observation strongly
implicated the fact that a persisting in£ammatory response in late
nonhealing wounds did not explain the observed dysregulation
and, moreover, leptin-mediated readjustment of arginase express-
ion in this model of impaired skin repair.
DISCUSSION
Wound healing of the skin is a highly coordinated process that
¢nally leads to at-least partial reconstruction of the injured tissue.
Recent data evidenced an important role of the short-lived med-
iator NO in skin repair (Frank et al, 2002).The synthesis of NO is
catalyzed by NOS, which exists in three di¡erent isoforms
(Moncada et al, 1991; Alderton et al, 2001). Nevertheless, recent
work from iNOS-de¢cient mice identi¢ed iNOS-derived NO
as pivotal in wound healing (Yamasaki et al, 1998). In line, inhibi-
tion of iNOS enzymatic activity during repair using N6 -(imi-
noethyl)-L-lysine evidenced a potent e¡ect of iNOS-derived
NO on epithelial gene expression leading to severely impaired
reepithelialization movements (Frank et al, 1999; Stallmeyer et al,
1999; Frank et al, 2000a). L-Arginine represents the only substrate
for NOS enzymatic activity, which ¢nally releases citrulline and
NO (Alderton et al, 2001; Moncada et al, 1991). Most important,
this enzymatic reaction links the long-known observation that L-
arginine was implicated in wound healing with the important
potency of NO to drive cutaneous repair. Twenty-¢ve years ago,
an initial study demonstrated that L-arginine-de¢cient rats
showed an impaired wound repair, as assessed by decreased
wound breaking strength and collagen deposition (Seifter et al,
1978). Consistently, wound £uids were characterized by low levels
of L-arginine, which directly implicated a consumption of L-argi-
nine at the wound site. Moreover, citrulline and nitrite, products
of NOS activity, peaked within the early, in£ammatory phase of
healing (Albina et al, 1990). This ¢nding was consistent with
recently published data demonstrating that the iNOS isoform is
expressed during wound in£ammation represents the predomi-
nant source of NO that ¢nally drives tissue regeneration (Frank
et al, 1998; Yamasaki et al, 1998; Frank et al, 1999). Nevertheless,
L-arginine levels in wound £uids remain low when repair goes
on, as the amino acid is subject to the catalytic activities of
arginases later in repair, releasing measurable amounts of or-
nithine into the wound £uids (Albina et al, 1990).
Nevertheless, there were no data available concerning arginase
expression that might be correlated with published data on
arginase activities in wounds. In general, mammals express two
arginase isoenzymes (Wu and Morris, 1998; for a review). We
detected both arginase isoenzymes upon injury at the wound site.
Arginase expression and activity were clearly restricted to the
in£ammatory phase of healing. Nevertheless, we found arginase
protein to be predominantly expressed at the epithelial margin of
the wound and not within the in£ammatory in¢ltrate that mark-
edly consists of activated mf at day 5 postwounding. Because
iNOS (Frank et al, 1998) is temporally coinduced with both argi-
nases (this study) between day 3 and 5 postwounding, one must
consider that L-arginine might be a limiting factor for the
activity of either the iNOS or the arginase biosynthetic pathways
at the wound site. This consideration was supported by our
observation that both arginase isoenzymes and the iNOS protein
were colocalized in the same subset of keratinocytes located at the
margins of the wound and in direct contact to the developing
granulation tissue. In line with this condition in wound repair, a
very recent article by Bruch-Gerharz et al (2003) demonstrates
that arginase-1 was overexpressed and, moreover, colocalized in
hyperproliferative keratinocytes but not within the in£ammatory
in¢ltrate of psoriatic lesions in humans.
Additionally, in vitro studies suggested that arginase and iNOS
indeed can compete for their L-arginine substrate, because
interference with arginase activities subsequently in£uenced NO
release from a variety of cell types (Hecker et al, 1995; Hey et al,
1997; Gotoh and Mori, 1999; Li et al, 2001). Because wound £uids
were almost completely depleted of L-arginine (Albina et al, 1988,
1993), this argues, with respect to the observed iNOS (Frank et al,
1999) and arginase activities (this study), that the L-arginine sub-
strate is most likely to represent the limiting factor for NOS or
arginase activities. Importantly, in vivo data from psoriatic lesions
strongly suggested a substrate competition of arginase and iNOS
in keratinocytes also for in£ammatory conditions in the skin
(Bruch-Gerharz et al, 2003). In accordance with our observations
on murine PAM 212 keratinocytes, Bruch-Gerharz and colleagues
demonstrated a moderate downregulation of arginase-1 by Th1
cytokines in primary human keratinocytes. It is reasonable to sug-
gest an antagonistic interaction between iNOS and arginase-1 also
for wound healing conditions, as both enzymes are reciprocally
regulated byTh1-type and Th2-type cytokines. Th1 cytokines in-
duce iNOS and downregulate arginase expression, whereas Th2
cytokines induce arginase and suppress iNOS (Corraliza et al,
1995; Modolell et al, 1995). Elevated NO synthesis contributes to
the limitation of immune-mediated in£ammatory processes (Kolb
and Kolb-Bachofen, 1998; Kubes, 2000). Thus, our observations on
elevated arginase-1 expression and activity in the absence of iNOS
in delayed repair suggest that the resulting low levels of NO
might participate in uncontrolled and chronic in£ammatory re-
sponses in wounds of diabetic mice (Wetzler et al, 2000). In line,
inhibition of wound-derived NO synthesis severely impaired re-
epithelialization processes after skin injury (Stallmeyer et al, 1999).
It was interesting to recognize that impaired healing of wounds in
diabetic animals was characterized by a severely disturbed balance
of iNOS and arginase expression (this study). Thus, a more or less
complete consumption of limiting amounts of L-arginine by argi-
nase-1 in the absence of iNOS during chronic, nonhealing wound
conditions strongly supports the idea of a balanced conversion of
L-arginine as a prerequisite for normal repair.
This hypothesis is further supported by the Km and Vmax va-
lues for arginase and NOS, which indicate similar rates of sub-
strate usage at low L-arginine concentrations (Grody et al, 1987;
Reczkowski and Ash, 1994; Gri⁄th and Stuehr, 1995; Wu and
Morris, 1998). Because wound £uids, representing the extracellu-
lar compartment in wound tissue, were characterized by lowest
concentrations of L-arginine (Albina et al, 1988, 1993), it is tempt-
ing to speculate that the competition of iNOS and the arginases
for intracellular pools of substrate might be further aggravated.
Consistently, the dietary supplementation of L-arginine improved
wound repair in animal models (Seifter et al, 1978) as well as in
humans (Barbul et al, 1990; Kirk et al, 1993), suggesting L-arginine
as a rate-limiting factor in skin repair. Indeed, a most recent study
reported that the bene¢cial e¡ects of an L-arginine supplementa-
tion was coupled to the presence of iNOS, because the loss of a
functional iNOS gene in iNOS-de¢cient animals abrogated the
bene¢cial e¡ects of L-arginine on wound healing (Shi et al, 2000).
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Moreover, leptin supplementation improves wound repair in
diabetic ob/ob mice (Frank et al, 2000b; Ring et al, 2000), and this
was, again, clearly paralleled by a readjustment of initially dysre-
gulated iNOS (early after wounding) and arginases (late wounds)
in the animals. Importantly, adjustment of dysregulated arginase
expression after leptin treatment was not due to an attenuation of
the prolonged in¢ltration of mf during impaired repair. Thus,
we observed a downregulation of arginase expression and activity
during leptin-improved repair in ob/ob mice in the presence of
large numbers of persisting mf in¢ltrate.This observation clearly
demonstrates the fact that the prolonged in£ammatory response
might not serve as simple explanation for increased arginase
Figure 6. Improved repair is associated with a readjustment of dysregulated arginase and iNOS expression. (a) Administered leptin is biologi-
cally active. Regulation of blood glucose levels 3 h after systemic application of recombinant leptin. po0.01 (Student’s t test) compared with PBS-treated
animals (top left panel). ob/obmice were treated systemically with leptin (2 mg/g body weight) for 13 d.The body weight of the animals was monitored (bottom
left panel). po0.01 (Student’s t test) compared with PBS-treated animals. Bars, mean7SD obtained from nine individual animals (n¼ 9). Presence of scab-
covered wounds after 13-d treatment with PBS or leptin as indicated (bottom right panel). po0.01 (Student’s t test) compared with PBS-treated animals.
Bars, mean7SD of wounds (n¼ 54) obtained from nine individual animals. (b) RNase protection assay showing the regulation of arginase-1 and arginase-2
mRNA expression in PBS- and leptin-treated diabetic ob/ob mice as indicated. The time after injury is indicated at the top of each lane. Ctrl skin, back skin
biopsies of nonwounded mice. Every experimental data point refers to 16 wounds (n¼16) isolated from 4 mice. Two independent experimental series are
shown (#I, #II). GAPDH mRNA expression is shown as a loading control. (c) Arginase-1 and arginase-2 protein in 13-d wounds isolated from PBS- and
leptin-treated ob/ob mice. Every experimental data point refers to 10 wounds (n¼10) isolated from 5 individual animals. One representative experiment is
shown. A Ponceau S staining of the immunoblot is used as a loading control. (d) Arginase activity assay in tissue homogenates from 13-d wounds isolated
from PBS- or leptin-injected ob/ob mice. Arginase activity is given as mg of urea per mg of protein per h. po0.01 (Student’s t test) as indicated by the
bracket. Bars, mean7SD obtained from wounds (n¼ 24) isolated from animals (n¼12) from three independent animal experiments. (e) RNase protection
assay showing iNOS mRNA expression in PBS- and leptin-treated ob/ob mice as indicated. The time after injury is indicated at the top of each lane. Ctrl
skin, back skin biopsies of nonwounded mice. Every experimental data point refers to 16 wounds (n¼16) isolated from 4 mice. GAPDH mRNA expression
is shown as a loading control. (f ) iNOS protein in wounds isolated from PBS- and leptin-treated ob/ob mice as indicated. Every experimental data point
refers to 8 wounds (n¼ 8) isolated from 4 individual animals. One representative experiment is shown for (e,f ). (g) RNase protection assay demonstrating
the in¢ltration kinetics of mf into wounds of PBS- and leptin-treated ob/ob mice. A quanti¢cation of lysozyme M (marker for mf) mRNA (x-fold
induction compared to control skin) is shown. n.s., not signi¢cant (Student’s t test) as indicated by the brackets. Bars, mean7SD obtained from wounds
(n¼ 48) isolated from animals (n¼12) from three independent animal experiments. (h) In situ determination of mf (F4/80) in 13-d wounds of PBS- and
leptin- treated ob/ob mice as indicated. M, macrophage.
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expression and activity during impaired wound healing. In line,
recent work demonstrated increased arginase activities in condi-
tions of impaired healing in humans. Chronic venous ulcers as
well as diabetic foot ulcers were characterized by elevated levels
of arginase activity ( Jude et al, 1999; Abd-El-Aleem et al, 2000).
Nevertheless, both chronic wound conditions in humans were re-
ported to show an increased NOS activity. These ¢ndings stand
in contrast to chronic healing conditions in the diabetic mouse
models, where a normally balanced L-arginine consumption was
shifted toward the arginase enzymatic pathway. Thus, it is not
clear yet which L-arginine-utilizing biosynthetic pathway might
predominate and account for a dysregulated L-arginine consump-
tion in chronic wounds in humans.
In summary, we demonstrated an induction of the arginase en-
zymatic system upon skin injury in mice, which paralleled the
well-established expressional and activity kinetics of the iNOS
after injury. Furthermore, impaired healing was associated with
a markedly increased arginase activity that was predominantly
due the presence of the arginase-1 isoform. Improved healing,
consistently, was characterized by a readjustment of iNOS and
arginases at the wound site. Thus, one must consider a balanced
presence of the iNOS as well as the arginases as a prerequisite to
drive an e⁄cient skin repair.
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